Literature DB >> 21252661

Nursing home acquired pneumonia: approach to management.

Ali A El-Solh1.   

Abstract

PURPOSE OF REVIEW: Pneumonia is among the leading causes of mortality in nursing home residents and a primary reason for transfer to acute care facilities. Compared with community-dwelling individuals, residents of long-term care facilities have extensive underlying medical illnesses and more functional disabilities and are at increased risk of acquiring drug-resistant pathogens. This review focuses on recent recommendations for diagnostic work up, validity of prognostic models, and current approach to treatment of nursing home acquired pneumonia (NHAP). RECENT
FINDINGS: The inconsistency in defining NHAP is considered a potential hindrance for a uniform approach to the management of pneumonia. Diagnostic evaluation varies between facilities and depends on severity of illness and access to laboratory facilities. The role of prognostic models in stratifying severity of disease remains largely unknown due to paucity of studies and lack of a specific scoring system for hospitalized patients with NHAP. A controversy still exists concerning the best therapeutic option for NHAP, but it is reasonable to believe that each setting is adapting the existing evidence according to the best local practice.
SUMMARY: A unified approach to defining, assessing, and stratifying pneumonia is essential to decrease morbidity and mortality in nursing home residents. High-quality randomized, controlled trials examining empiric antibiotic therapy are needed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21252661     DOI: 10.1097/QCO.0b013e328343b6cc

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  8 in total

Review 1.  Predictors of mortality for nursing home-acquired pneumonia: a systematic review.

Authors:  Naveen Dhawan; Naushira Pandya; Michael Khalili; Manuel Bautista; Anurag Duggal; Jaya Bahl; Vineet Gupta
Journal:  Biomed Res Int       Date:  2015-03-02       Impact factor: 3.411

2.  Clinical characteristics of nursing home-acquired pneumonia in elderly patients admitted to a Korean teaching hospital.

Authors:  Seong Joo Koh; Jong Hoo Lee
Journal:  Korean J Intern Med       Date:  2015-08-27       Impact factor: 2.884

3.  Accuracy of alpha amylase in diagnosing microaspiration in intubated critically-ill patients.

Authors:  Florent Dewavrin; Farid Zerimech; Alexandre Boyer; Patrice Maboudou; Malika Balduyck; Alain Duhamel; Saad Nseir
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

4.  Microbiological evaluation of LOCATOR® Legacy attachments: A cross-sectional clinical study.

Authors:  Ursina Nagy; Christophe Guédat; Catherine Giannopoulou; Martin Schimmel; Frauke Müller; Murali Srinivasan
Journal:  Clin Exp Dent Res       Date:  2019-07-18

5.  Incidence of Antibiotic Treatment Failure in Patients with Nursing Home-Acquired Pneumonia and Community Acquired Pneumonia.

Authors:  Mariana Lopes; Gonçalo Alves Silva; Rui Filipe Nogueira; Daniela Marado; João Gonçalves; Carlos Athayde; Dilva Silva; Ana Figueiredo; Jorge Fortuna; Armando Carvalho
Journal:  Infect Dis Rep       Date:  2021-01-05

6.  Incidence and economical effects of pneumonia in the older population living in French nursing homes: design and methods of the INCUR study.

Authors:  Laurent Demougeot; Yves Rolland; Stéphane Gérard; Delphine Pennetier; Marilyne Duboué; Bruno Vellas; Matteo Cesari
Journal:  BMC Public Health       Date:  2013-09-17       Impact factor: 3.295

7.  Nursing home-acquired pneumonia: course and management in the emergency department.

Authors:  Syed Imran Ayaz; Nadia Haque; Claire Pearson; Patrick Medado; Duane Robinson; Robert Wahl; Marcus Zervos; Brian J O'Neil
Journal:  Int J Emerg Med       Date:  2014-05-12

8.  Facility characteristics as independent prognostic factors of nursing home-acquired pneumonia.

Authors:  Che Wan Lim; Younghoon Choi; Chang Hyeok An; Sang Joon Park; Hee-Jin Hwang; Jae Ho Chung; Joo-Won Min
Journal:  Korean J Intern Med       Date:  2016-02-02       Impact factor: 2.884

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.